This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
600
NBI-1065845 tablets
Neurocrine Clinical Site
Little Rock, Arkansas, United States
RECRUITINGNumber of Participants with Treatment-emergent Adverse Events (TEAEs)
Time frame: Baseline through Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Neurocrine Clinical Site
Orange, California, United States
RECRUITINGNeurocrine Clinical Site
Pico Rivera, California, United States
RECRUITINGNeurocrine Clinical Site
Upland, California, United States
RECRUITINGNeurocrine Clinical Site
Hollywood, Florida, United States
RECRUITINGNeurocrine Clinical Site
Maitland, Florida, United States
RECRUITINGNeurocrine Clinical Site
Tampa, Florida, United States
RECRUITINGNeurocrine Clinical Site
Atlanta, Georgia, United States
RECRUITINGNeurocrine Clinical Site
Boston, Massachusetts, United States
RECRUITINGNeurocrine Clinical Site
Watertown, Massachusetts, United States
RECRUITING...and 8 more locations